Galectin Therapeutics (GALT)

• Market cap: $344M
• 1 day: -9.6%
• 5 days: 14.26%
• 1 month: 42.44%
• 3 months: 300.75%
• 6 months: 214.04%
• Year to date: 358.97%
• 1 year: 98.15%
• 5 years: 80.2%
• 10 years: 153.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 15

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

66% more capital invested

Capital invested by funds: $12.6M [Q1] → $21M (+$8.32M) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

0.18% less ownership

Funds ownership: 16.59% [Q1] → 16.41% (-0.18%) [Q2]

9% less funds holding

Funds holding: 92 [Q1] → 84 (-8) [Q2]

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

66% less call options, than puts

Call options by funds: $355K | Put options by funds: $1.05M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6
• Avg. target: $6
• High target: $6

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Keller	$6	Buy Reiterated	14 Aug 2025
HC Wainwright & Co. Joseph Pantginis	$6	Buy Assumed	17 Jun 2025